- Home
- PRVA vs APGE Comparison
PRVA vs APGE Comparison
Compare PRVA & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRVA
- APGE
- Stock Information
- Founded
- PRVA 2007
- APGE 2022
- Country
- PRVA United States
- APGE United States
- Employees
- PRVA N/A
- APGE N/A
- Industry
- PRVA Retail: Computer Software & Peripheral Equipment
- APGE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PRVA Technology
- APGE Health Care
- Exchange
- PRVA Nasdaq
- APGE Nasdaq
- Market Cap
- PRVA 2.5B
- APGE 3.0B
- IPO Year
- PRVA 2021
- APGE 2023
- Fundamental
- Price
- PRVA $20.42
- APGE $47.45
- Analyst Decision
- PRVA Buy
- APGE Strong Buy
- Analyst Count
- PRVA 13
- APGE 6
- Target Price
- PRVA $24.46
- APGE $75.40
- AVG Volume (30 Days)
- PRVA 655.3K
- APGE 623.1K
- Earning Date
- PRVA 11-07-2024
- APGE 11-12-2024
- Dividend Yield
- PRVA N/A
- APGE N/A
- EPS Growth
- PRVA N/A
- APGE N/A
- EPS
- PRVA 0.11
- APGE N/A
- Revenue
- PRVA $1,716,318,000.00
- APGE N/A
- Revenue This Year
- PRVA $78.44
- APGE N/A
- Revenue Next Year
- PRVA $11.43
- APGE N/A
- P/E Ratio
- PRVA $186.08
- APGE N/A
- Revenue Growth
- PRVA 8.54
- APGE N/A
- 52 Week Low
- PRVA $15.92
- APGE $25.85
- 52 Week High
- PRVA $24.30
- APGE $72.29
- Technical
- Relative Strength Index (RSI)
- PRVA 44.42
- APGE 49.00
- Support Level
- PRVA $19.82
- APGE $43.69
- Resistance Level
- PRVA $21.95
- APGE $48.85
- Average True Range (ATR)
- PRVA 0.87
- APGE 3.97
- MACD
- PRVA -0.24
- APGE 0.26
- Stochastic Oscillator
- PRVA 16.93
- APGE 48.79
About PRVA Privia Health Group Inc.
Privia Health Group Inc is a technology-driven, national physician-enablement company. It collaborates with medical groups, health plans, and health systems to optimize physician practices, improve patient experiences, and reward doctors for delivering high-value care in both in-person and virtual care settings.
About APGE Apogee Therapeutics Inc.
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. Its two programs are APG777 and APG808, which initially develop for treating AD and COPD, respectively.